A Study of IBI362 in Chinese Patients With Type 2 Diabetes

NCT04965506 on ClinicalTrials.gov · last registry update 2023-12-27

An unusually large phase 2: 252 participants, more than double the 110 typical for the stage. The sponsor logged completion for 28 April 2022. Primary outcome, as filed: The change in HbA1c from baseline to 20 weeks. dulaglutide is already approved in the US for type 2 diabetes, so this is asking a further question rather than establishing the drug works at all.

Status: COMPLETED
Phase: P2
Drug: dulaglutide
Trulicity
Sponsor: Innovent Biologics (Suzhou) Co. Ltd.
Sponsor type: Industry
Enrollment: 252
Started: 2021-09-06
Primary completion: 2022-04-28 actual

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

The change in HbA1c from baseline to 20 weeks

Conditions studied

Type 2 Diabetes

Every field above is taken directly from the registry record. See all detected changes across the class, or the dulaglutide page for this molecule’s full trial and approval history.